




INVESTOR PRESENTATION

Summer/Fall 2024



LEGAL DISCLAIMER

This presentation and associated commentary may contain forward-looking statements, including statements regarding expectations of future results of operations or financial performance of Doximity, market size and growth opportunities, the calculation of certain of our key financial and operating metrics, capital expenditures, plans for future operations, competitive position, technological capabilities, and strategic relationships, general business conditions and the assumptions underlying those statements.

Any forward-looking statements contained in this presentation and associated commentary are based upon Doximity's historical performance and its plans, estimates and expectations as of the dates noted in this presentation, and are not a representation that such plans, estimates, or expectations have been or will be achieved. These forward-looking statements represent Doximity's expectations as of the dates noted in this presentation. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all. Subsequent events may cause these expectations to change, and Doximity disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including, but not limited to, those related to our business and financial performance, our ability to attract and retain customers, our ability to develop new products and services and enhance existing products and services, our ability to respond rapidly to emerging technology trends, our ability to execute on our business strategy, our ability to compete effectively and our ability to manage growth.

Additional risks and uncertainties that could affect Doximity's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's filings with the Securities and Exchange Commission on Form 10-K and subsequent Form 10-Qs. These materials are available on our investor relations website at investors.doximity.com under the Financials section and on the SEC's website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Doximity makes with the SEC from time to time. In addition to financial information presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation and associated commentary may include certain non-GAAP financial measures (including on a forward-looking basis) such as Adjusted EBITDA and Free Cash Flow. Definitions and reconciliations of non-GAAP measures to their most directly comparable GAAP counterparts are available in our most recent Form 10-K or 10-Q on the company's investor relations website at investors.doximity.com.

THE DIGITAL PLATFORM FOR DOCTORS

Leading Network

80%⁺

of all U.S.
Physicians¹

Blue Chip Clients

20/20

Top Hospitals
and Health Systems
Top Pharmaceutical
Manufacturers³

Growth and Profit

22%

Subscription
Revenue Growth⁵

>525K


Workflow Unique
Active Providers²

118%

Net Revenue
Retention Rate⁴

45%

Adj. EBITDA
Margin⁶



1. As of 6/30/23.

2. For fiscal quarter ending 6/30/23.

3. Top 20 Pharmaceutical Manufacturers based on data from Evaluate, Top 20 hospitals based on U.S. News & World Report's Best Hospitals U.S. News Best Hospitals 2023-2024 Honor Roll.

4. For the trailing twelve month (TTM) period ending 6/30/23. Refer to appendix for the definition of Net Revenue Retention.

5. For the trailing twelve month (TTM) period ending 6/30/23.

6. For the trailing twelve month (TTM) period ending 6/30/23. Refer to appendix for the definition and non-GAAP reconciliation of Adjusted EBITDA and Adjusted EBITDA Margin.

GLARING DAY-TO-DAY INEFFICIENCIES

80%

of US HC documents sent via
snail mail and fax¹


78%

of physicians **report burnout**, with health
IT as one of least satisfying factors²



BRINGING TECH TO MEDICINE

Inspired by enterprise tech



Note: These are not customers or partners, these are illustrative examples of premier enterprise tech solutions in their respective markets.

Purpose-built for healthcare




4.8 out of 5, 150K+ Ratings & Reviews¹




“This app has changed my professional life.”

PURPOSE BUILT FOR HEALTHCARE



Professional Network



Newsfeed




Productivity



OUR COMMERCIAL SOLUTIONS


Marketing



Educate on Latest News & Treatments

Relevance and personalization drive Rx's & Referrals

Hiring



Uncover Passive Candidates

Find specialized talent

Workflow




Reduce No-Shows & Leakage

*#1 "Best in KLAS" Telehealth Video Conferencing
Hundreds of thousands of on-call schedules*



MARKETING SOLUTIONS

Largest Revenue Driver: Marketing Solutions



Leading Network

>73% of healthcare spend
is decided by Doctors¹



Subscription Pricing Model

1. Audience (e.g. specialty)
2. Number of audience members
3. Type and number of modules



17:1 ROI²
LexisNexis



11:1 ROI³
IQVIA


1. Center for Medicare & Medicaid Services, including categories of hospital care, physician & clinical services, retail prescription drugs, nursing care facilities & continuing care retirement communities, home health care, & durable medical equipment.

2. Our ROI studies are conducted using data from third party provider LexisNexis Risk Solutions for our health system customers. Median ROI as measured by third party claims data analysis of shared patient lift from new referring providers. As of September 2022.

3. Actual results vary based on therapy area, product price, product maturity, and the number of months over which the ROI was measured. As of September 2022.

LAND AND EXPAND SALES MOTION


1 Land Initial Brands or Service Lines



Pharmaceutical
Manufacturer

Health
System


2 Expand to Add'l Brands or Service Lines



Pharmaceutical
Manufacturer

Health
System


3 Expand Number & Type of Modules Utilized



Pharmaceutical
Manufacturer


Health
System

CATEGORIES OF MODULES




Awareness

Build brand equity and communicate key messages



Interactivity


Replace face-to-face interactions with digital alternatives



Peer

Connect and build professional relationships


LARGE & GROWING TOTAL ADDRESSABLE MARKET




1. Pharmaceutical Marketing TAM represents total annual marketing spend by Pharmaceutical Manufacturers to Doctors. Source: IQVIA 2019 US ChannelDynamics and Kantar Media Intelligence, US Healthcare Ad Spend
2. Health System Marketing and Staffing TAM represents Hospital Marketing Spend, Revenue Opportunity from Locum Tenens solutions and Permanent Staffing solutions. Source: BIA Advisory Services, GVR, Kaiser Family Foundation and the AAPPR In-House Physician and Provider Recruitment benchmarking
3. Telehealth TAM represents revenue opportunity from Telehealth sales to care locations and individuals. Source: IBISWorld

~430 RX BRANDS WITH \$100M+ IN U.S. SALES


Estimated Doximity Share of HCP Marketing Budgets at Customers¹



Note: Each box represents one brand with \$100M+ in U.S. sales




Est. Share of Total HCP Marketing Budgets¹



Q1 KEY METRICS

LAND


Number of Customers w/ \$100k+ of Revenue¹



&


EXPAND

Net Revenue Retention²




HIGH GROWTH REVENUE & ATTRACTIVE MARGIN PROFILE

Revenue¹



Adj. EBITDA & Margin^{1,2}



FOUNDER-LED, MISSION DRIVEN



Jeff Tangney
CEO & Co-Founder



Shari Buck
Co-Founder



Dr. Nate Gross
CSO & Co-Founder



Anna Bryson
CFO



Jey Balachandran
CTO



Paul Jorgensen
CRO



Craig Overpeck
SVP Commercial Operations




Ben Greenberg
SVP Commercial Products



Joel Davis
SVP Product



Jennifer Chaloehtiarana
General Counsel



976
EMPLOYEES¹

1/3+
IN R&D¹

¹ As of June 30, 2023.

COMPANY HIGHLIGHTS

- 1 Leading digital platform for doctors
- 2 Powerful network effects
- 3 Sustainable high-growth revenue & profitability
- 4 Veteran vertical team
- 5 Massive near-term market opportunity fueled by shift to digital

APPENDIX: NON-GAAP FINANCIAL MEASURES

To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance:

Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of stock-based compensation expense, amortization of acquired intangible assets, change in fair value of contingent earn-out consideration liability, expenses associated with acquisitions, and restructuring charges from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.

Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, change in fair value of contingent earn-out consideration liability, restructuring charges, and other income, net. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.

Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.

We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Business Metrics

Net revenue retention rate: Net revenue retention rate is calculated by taking the trailing 12-month ("TTM") subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.

Customers with trailing 12-month subscription revenue greater than \$100,000: The number of customers with TTM subscription revenue greater than \$100,000 is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than \$100,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

APPENDIX: ADJUSTED EBITDA & MARGIN NON-GAAP RECONCILIATION

	Year Ended March 31,					TTM
	2019	2020	2021	2022	2023	Q1 FY24
	(in thousands)					(in thousands)
Net Income	\$7,833	\$29,737	\$50,210	\$154,783	\$112,818	\$118,841
Adjustments:						
Acquisition and other related expenses	–	1,158	496	254	30	–
Stock-based compensation	2,343	2,353	7,252	31,442	47,834	52,329
Depreciation and amortization	551	900	3,702	5,040	10,283	10,517
Change in fair value of contingent earn-out consideration liability	–	–	–	–	728	1,051
Income tax expense (benefit)	98	(6,223)	7,559	(40,778)	20,338	26,351
Other income, net	(1,010)	(1,351)	(4,466)	(469)	(8,048)	(12,083)
Adjusted EBITDA	\$9,815	\$26,574	\$64,753	\$150,272	\$183,983	\$197,006
Revenue	\$85,695	\$116,388	\$206,897	\$343,548	\$419,052	\$436,882
Adjusted EBITDA Margin	11%	23%	31%	44%	44%	45%